n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Hea...(al (GISSI-P) published in The Lancet in ...),Health

Date:9/2/2008

al (GISSI-P) published in The Lancet in 19993, of 11,323 post-myocardial infarction (<3 months previous) patients who received n-3 PUFAs (1 g daily), vitamin E, both, or no treatment (control group), in addition to standard pharmacological treatment and lifestyle advice (approximately 70% of patients were already consuming fish at least once per week). The total mortality was reduced by 20%, with a 45% reduction in sudden death in the n-3 PUFAs group. The GISSI-P trial had shown that 1 g n-3 PUFAs could save 5.7 lives per 1,000 treated patients per year. Interestingly, a sub-analysis from GISSI-P showed that the clinical benefits observed were independent of whether or not patients were also receiving a statin.

Further information about the GISSI-group can be found at http://www.gissi.org/.

*The Protocol is sponsored by Gruppo di Ricerca GISSI and partially supported by: AstraZeneca, Societa Prodotti Antibiotici, Sigma Tau, Pfizer

About heart failure

Heart failure is not a single disease, but instead is the end result of several cardiac disease processes, and is the principle complication of virtually all forms of heart disease. In Europe and the United States altogether, around 10 million people have been diagnosed with chronic heart failure. It places a huge burden on society and despite major advances in drug therapy for symptomatic heart failure, during the past two decades, hospitalisations continue to increase. Therefore, novel and effective treatment is necessary to fulfil unmet needs in the management of heart failure.

About Omacor(R)

This highly purified n-3 polyunsaturated fatty acid (n-3 PUFA) ethyl esters 90, marketed by Solvay under the trade name Omacor(R), is already indicated-as an adjuvant to standard therapies (statins, antiplatelet drugs, beta-blockers and ACE inhibitors)- in Europe and some Middle East countries for secondary prevention of myocardial infar
'/>"/>

SOURCE Solvay Pharmaceuticals Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel
2. National Study Shows Magnesium Sulfate Reduces Risk of Cerebral Palsy in Premature Births
3. Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
4. DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education
5. New Study: Pine Bark Significantly Reduces Menstrual Pain
6. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
7. Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
8. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
9. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
10. CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI
11. Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%